Entrada Therapeutics Inc
TRDA5.885USD
+0.085+1.47%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
223.29MCap. mercado
9.01P/E TTM
Más Datos de Entrada Therapeutics Inc Compañía
Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a class of medicines, which engages intracellular targets that have long been considered inaccessible. The Company’s Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Through its proprietary, highly versatile and modular EEV platform (EEV Platform), the Company is building a robust development portfolio of therapeutic candidates. Its first two drug candidates, ENTR-601-44 and VX-670, are in clinical trials. VX-670 for dystrophy type 1 (DM1) is designed to block the triplet repeats in the messenger RNA (mRNA). ENTR-601-44 is in a Phase I clinical trial. The Company also announced the selection of additional clinical candidates within its Duchenne franchise, ENTR-601-45 and ENTR-601-50.
Información de la empresa
Símbolo de cotizaciónTRDA
Nombre de la empresaEntrada Therapeutics Inc
Fecha de salida a bolsaOct 29, 2021
Director ejecutivoMr. Dipal Doshi
Número de empleados183
Tipo de seguridadOrdinary Share
Fin del año fiscalOct 29
DirecciónOne Design Center Place
CiudadBOSTON
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal02210
Teléfono18573051825
Sitio Webhttps://www.entradatx.com/
Símbolo de cotizaciónTRDA
Fecha de salida a bolsaOct 29, 2021
Director ejecutivoMr. Dipal Doshi
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Peter S. Kim, Ph.D.
Dr. Peter S. Kim, Ph.D.
Director
Director
104.33K
-10.60%
Dr. Natarajan Sethuraman, Ph.D.
Dr. Natarajan Sethuraman, Ph.D.
President of Research and Development
President of Research and Development
82.24K
-31.79%
Mr. Kory James Wentworth, CPA
Mr. Kory James Wentworth, CPA
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
31.84K
-27.89%
Mr. Nathan J. Dowden
Mr. Nathan J. Dowden
President, Chief Operating Officer
President, Chief Operating Officer
11.80K
-77.74%
Ms. Gina Chapman
Ms. Gina Chapman
Independent Director
Independent Director
--
--
Dr. Bernhardt (Bernie) Zeiher, M.D.
Dr. Bernhardt (Bernie) Zeiher, M.D.
Independent Director
Independent Director
--
--
Dr. Kush M. Parmar, M.D., Ph.D.
Dr. Kush M. Parmar, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Dipal Doshi
Mr. Dipal Doshi
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Ms. Mary T. Thistle, CPA
Ms. Mary T. Thistle, CPA
Independent Director
Independent Director
--
--
Dr. Mahalakshmi (Maha) Radhakrishnan, M.D.
Dr. Mahalakshmi (Maha) Radhakrishnan, M.D.
Independent Director
Independent Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Peter S. Kim, Ph.D.
Dr. Peter S. Kim, Ph.D.
Director
Director
104.33K
-10.60%
Dr. Natarajan Sethuraman, Ph.D.
Dr. Natarajan Sethuraman, Ph.D.
President of Research and Development
President of Research and Development
82.24K
-31.79%
Mr. Kory James Wentworth, CPA
Mr. Kory James Wentworth, CPA
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
31.84K
-27.89%
Mr. Nathan J. Dowden
Mr. Nathan J. Dowden
President, Chief Operating Officer
President, Chief Operating Officer
11.80K
-77.74%
Ms. Gina Chapman
Ms. Gina Chapman
Independent Director
Independent Director
--
--
Dr. Bernhardt (Bernie) Zeiher, M.D.
Dr. Bernhardt (Bernie) Zeiher, M.D.
Independent Director
Independent Director
--
--
Desglose de ingresos
FY2025Q1
FY2024
FY2023
FY2023Q2
Sin datos
Por regiónUSD
Nombre
Ganancia
Proporción
United States
20.56M
0.00%
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: vie., 18 de jul
Actualizado: vie., 18 de jul
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Baker Bros. Advisors LP
12.82%
MPM Capital Inc.
11.54%
5AM Ventures
11.21%
T. Rowe Price Associates, Inc.
7.11%
F. Hoffman La Roche, Ltd.
6.77%
Other
50.54%
Accionistas
Accionistas
Proporción
Baker Bros. Advisors LP
12.82%
MPM Capital Inc.
11.54%
5AM Ventures
11.21%
T. Rowe Price Associates, Inc.
7.11%
F. Hoffman La Roche, Ltd.
6.77%
Other
50.54%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor/Hedge Fund
28.19%
Investment Advisor
23.69%
Hedge Fund
14.14%
Corporation
11.35%
Venture Capital
11.34%
Private Equity
2.01%
Individual Investor
1.01%
Research Firm
0.54%
Pension Fund
0.22%
Other
7.51%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
226
35.27M
92.92%
-1.95M
2025Q1
237
37.05M
97.63%
-2.01M
2024Q4
222
37.20M
98.96%
+761.72K
2024Q3
209
35.09M
95.11%
-779.91K
2024Q2
193
34.68M
94.55%
+2.42M
2024Q1
185
31.33M
93.34%
-1.07M
2023Q4
174
31.30M
93.83%
-1.07M
2023Q3
167
31.14M
93.63%
-973.86K
2023Q2
154
30.75M
92.59%
+53.89K
2023Q1
141
30.00M
92.19%
-903.00K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Baker Bros. Advisors LP
4.87M
12.82%
--
--
Mar 31, 2025
MPM Capital Inc.
4.38M
11.54%
--
--
Mar 31, 2025
5AM Ventures
4.31M
11.35%
-100.00K
-2.27%
Jun 30, 2025
T. Rowe Price Associates, Inc.
2.70M
7.11%
-167.02K
-5.83%
Mar 31, 2025
F. Hoffman La Roche, Ltd.
2.57M
6.77%
-175.00K
-6.38%
Dec 31, 2024
Janus Henderson Investors
2.12M
5.59%
+41.29K
+1.98%
Mar 31, 2025
Merck & Co Inc
1.74M
4.58%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
1.73M
4.56%
+55.00
+0.00%
Mar 31, 2025
The Vanguard Group, Inc.
1.57M
4.14%
+111.36K
+7.62%
Mar 31, 2025
Fidelity Management & Research Company LLC
1.24M
3.27%
-160.10K
-11.44%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
Virtus LifeSci Biotech Clinical Trials ETF
0.77%
iShares Neuroscience and Healthcare ETF
0.36%
First Trust Dow Jones Select MicroCap Index Fund
0.27%
Harbor Human Capital Factor US Small Cap ETF
0.1%
Federated Hermes MDT Small Cap Core ETF
0.05%
iShares Micro-Cap ETF
0.04%
ProShares Ultra Nasdaq Biotechnology
0.03%
WisdomTree US SmallCap Fund
0.03%
Avantis US Small Cap Equity ETF
0.03%
Invesco Nasdaq Biotechnology ETF
0.03%
Ver más
Virtus LifeSci Biotech Clinical Trials ETF
Proporción0.77%
iShares Neuroscience and Healthcare ETF
Proporción0.36%
First Trust Dow Jones Select MicroCap Index Fund
Proporción0.27%
Harbor Human Capital Factor US Small Cap ETF
Proporción0.1%
Federated Hermes MDT Small Cap Core ETF
Proporción0.05%
iShares Micro-Cap ETF
Proporción0.04%
ProShares Ultra Nasdaq Biotechnology
Proporción0.03%
WisdomTree US SmallCap Fund
Proporción0.03%
Avantis US Small Cap Equity ETF
Proporción0.03%
Invesco Nasdaq Biotechnology ETF
Proporción0.03%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
